IAM 1363
Alternative Names: ENT H1; IAM-1363; IAM-H1Latest Information Update: 20 Jun 2024
Price :
$50 *
At a glance
- Originator Iambic Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Cancer
Most Recent Events
- 05 Apr 2024 Ppharmacokinetics data from a preclinical study in Cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 28 Mar 2024 Pharmacodynamics and adverse events data from the preclinical studies in Cancer released by Iambic Therapeutics
- 27 Mar 2024 Phase-I clinical trials in Cancer (Late-stage disease, Second-line therapy or greater, Combination therapy) in USA (PO) (NCT06253871)